We resume our landmark studies series looking at the pivotal study in Major Depressive Disorder (MDD), The STAR*D (Sequenced Treatment Alternatives to Relieve Depression) trial.

References:

https://pubmed.ncbi.nlm.nih.gov/12778843/

https://pubmed.ncbi.nlm.nih.gov/19880458/

https://jamanetwork.com/journals/jamapsychiatry/fullarticle/482026

https://pubmed.ncbi.nlm.nih.gov/15061154/

https://pubmed.ncbi.nlm.nih.gov/20370962/

https://pubmed.ncbi.nlm.nih.gov/37491091/

We have a special guest today to talk about one of our favorite topics... dogs! Most people might intuitively say that they feel like their dogs improve their mental health, but today, we look at the science with the leading expert on the subject.

Dr. Nancy Gee Profile: https://medschool.vcu.edu/about/portfolio/details/geen2/

References:

Dogs Supporting Human Health and Well-Being: A Biopsychosocial Approach: 

https://pubmed.ncbi.nlm.nih.gov/33860004/

Randomized Controlled Trials: https://pmc.ncbi.nlm.nih.gov/articles/PMC12728353/, https://pmc.ncbi.nlm.nih.gov/articles/PMC11714157/

Welcome back! Today, we are talking about Simtriyo, which has generated a lot of media attention recently given a newly minted FDA approval for ADHD.

References 

https://pmc.ncbi.nlm.nih.gov/articles/PMC12314114/

https://pmc.ncbi.nlm.nih.gov/articles/PMC12379780/

https://pubmed.ncbi.nlm.nih.gov/31776871/

https://pubmed.ncbi.nlm.nih.gov/40619095/

https://pubmed.ncbi.nlm.nih.gov/28731336/

https://pmc.ncbi.nlm.nih.gov/articles/PMC9426730/

Today we're starting a new type of series - looking at some of the most seminal studies in psychiatry. We're going to start with the CATIE Trial, which was published in 2005.

References:

https://www.nejm.org/doi/full/10.1056/NEJMoa051688

https://pubmed.ncbi.nlm.nih.gov/19594194/

https://pubmed.ncbi.nlm.nih.gov/17924259/

https://pubmed.ncbi.nlm.nih.gov/17286522/

https://www.nejm.org/doi/full/10.1056/NEJMoa061240

https://jamanetwork.com/journals/jamapsychiatry/fullarticle/209844

Apologies for our little hiatus - a couple of us had cross-country moves in June. But we're back! Today we have an episode on the rising use of recreational Kratom and pertinent tidbits to know from a psychiatry standpoint.

References:

• https://pmc.ncbi.nlm.nih.gov/articles/PMC8924421/

• https://www.ncbi.nlm.nih.gov/books/NBK585120/

• https://pmc.ncbi.nlm.nih.gov/articles/PMC10846393/

• https://pmc.ncbi.nlm.nih.gov/articles/PMC10177737/

Welcome back! Today, we are looking at Modafinil and it's nuanced use in psychiatry.

References:

1. Provigil (modafinil) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc. U.S. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfdadocs/label/2015/020717s037s038lbl.pdf

2. Schwartz JR. Modafinil in the treatment of excessive sleepiness. Drug Des Devel Ther. 2009;2:71–85.

3. Kaplan S, Goehring EL Jr, Engel T, et al. Cardiovascular outcomes associated with modafinil in patients with obstructive sleep apnea. Pharmacoepidemiol Drug Saf. 2018;27(11):1182–1190. doi:10.1002/pds.4642

4. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738. doi:10.1016/S2215-0366(18)30269-4

5. Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2013;74(11):1101–1107. doi:10.4088/JCP.13r08560

6. Bahji A, Mesbah-Oskui L. Comparative efficacy and safety of stimulant-type medications for depression: a systematic review and network meta-analysis. J Affect Disord. 2021;292:416–423. doi:10.1016/j.jad.2021.05.119

7. Nunez NA, Singh B, Jorgensen A, et al. Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: a meta-analysis of randomized controlled trials. Bipolar Disord. 2020;22(2):109–120. doi:10.1111/bdi.12859

Welcome Back! Today we are discussing the medication Naltrexone and its uses in psychiatry.

References:

• https://www.ncbi.nlm.nih.gov/books/NBK534811/

• https://pubmed.ncbi.nlm.nih.gov/24825644/

• https://pubmed.ncbi.nlm.nih.gov/26798982/

• https://www.nejm.org/doi/full/10.1056/NEJMct0801733

• https://pubmed.ncbi.nlm.nih.gov/26798982/

Welcome back! Today, we will be discussing the placebo effect.

References:

https://pubmed.ncbi.nlm.nih.gov/16503356/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003660/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556377/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714297/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694178/

https://www.psychiatrypodcast.com/psychiatry-psychotherapy-podcast/2018/11/19/understanding-placebo

Welcome back! Today we are talking all about Amantadine, and it's uses in psychiatry.

Welcome back! Today we are featuring the two FDA-approved medications for tardive dyskinesia, the VMAT2 inhibitors Valbenazine (Ingrezza) and Deutetrabenazine (Austedo).

References:

https://pubmed.ncbi.nlm.nih.gov/41626799/

https://www.ncbi.nlm.nih.gov/books/NBK548187/

https://pubmed.ncbi.nlm.nih.gov/41626799/